|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600120850 |
|
最近更新日期: Date of Last Refreshed on: |
2026-03-20 14:30:01 |
|
注册时间: Date of Registration: |
2026-03-20 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
房颤导管消融后患者早期行走的可行性及安全性:一项随机、非劣效性临床试验 |
|
Public title: |
Feasibility and safety of early walking after catheter ablation of atrial fibrillation: A randomized, non-inferiority clinical trial |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
房颤导管消融后患者早期行走的可行性及安全性:一项随机、非劣效性临床试验 |
|
Scientific title: |
Feasibility and safety of early walking after catheter ablation of atrial fibrillation: A randomized, non-inferiority clinical trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
梁斌 |
研究负责人: |
梁斌 |
|
Applicant: |
Liang Bin |
Study leader: |
Liang Bin |
|
申请注册联系人电话: Applicant telephone: |
+86 139 9423 5827 |
研究负责人电话: Study leader's telephone: |
+86 139 9423 5827 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
tyliangbin@163.com |
研究负责人电子邮件: Study leader's E-mail: |
tyliangbin@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山西省太原市五一路382号 |
研究负责人通讯地址: |
山西省太原市五一路382号 |
|
Applicant address: |
No. 382, Wuyi Road, Taiyuan City, Shanxi Province |
Study leader's address: |
No. 382, Wuyi Road, Taiyuan City, Shanxi Province |
|
申请注册联系人邮政编码: Applicant postcode: |
030000 |
研究负责人邮政编码: Study leader's postcode: |
030000 |
|
申请人所在单位: |
山西医科大学第二医院 |
||
|
Applicant's institution: |
The Second Hospital of Shanxi Medical University |
||
|
研究负责人所在单位: |
山西医科大学第二医院 |
||
|
Affiliation of the Leader: |
The Second Hospital of Shanxi Medical University |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
[2025] YX 第321号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
山西医科大学第二医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of the Second Hospital of Shanxi Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-01-12 00:00:00 |
||
|
伦理委员会联系人: |
李志芳 |
||
|
Contact Name of the ethic committee: |
Li Zhifang |
||
|
伦理委员会联系地址: |
山西省太原市五一路382号 |
||
|
Contact Address of the ethic committee: |
No. 382, Wuyi Road, Taiyuan City, Shanxi Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 159 3410 9777 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
gzrll_666@163.com |
|
研究实施负责(组长)单位: |
山西医科大学第二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Hospital of Shanxi Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山西省太原市五一路382号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 382, Wuyi Road, Taiyuan City, Shanxi Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
self-raised |
||||||||||||||||||||||
|
Target disease: |
atrial fibrillation |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
明确房颤患者导管消融治疗中鞘管拔除后4小时下地活动是否可以取代6小时甚至更长时间的下地活动,在不增加穿刺部位并发症的前提下,提高患者的舒适度与体验感,为临床指导房颤患者术后管理提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To clarify whether walking down the ground 4 hours after sheath removal can replace 6 hours or even longer walking down the ground in catheter ablation treatment of patients with atrial fibrillation, so as to improve patient comfort and experience without increasing complications at the puncture site. Provide basis for clinical guidance for postoperative management of patients with atrial fibrillation |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
(1)年龄为18-80岁; (2)行导管消融术的房颤患者; (3)签署知情同意书的患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Age 18-80 years old; 2.Patients with atrial fibrillation undergoing catheter ablation; 3.Patients who signed informed consent. |
||||||||||||||||||||||
|
排除标准: |
1,术前排除标准: (1)腹股沟附近或全身皮肤感染或炎症; (2)既往经股动脉或股静脉行介入手术或置管的患者; (3)存在血液系统疾病; (4)长期使用高剂量全身性类固醇药物; (5)患有严重合并症及并发症患者。 2.术中排除标准: 在获得患者知情同意后,患者接受合适的射频消融术。在消融过程中如果出现以下任何情况,患者被进一步排除在研究之外: (1)尝试股动脉通路消融或不慎穿刺股动脉; (2)手术中发生严重的大出血、血栓或其他严重并发症; (3)针刺或插入导管鞘困难; (4)鞘管位置放置不正确。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Preoperative Exclusion Criteria: (1) Presence of skin infection or inflammation in the groin area or systemically; (2) Prior history of interventional surgery or catheterization via the femoral artery or vein; (3) Presence of hematological disorders; (4) Long-term use of high-dose systemic corticosteroids; (5) Presence of severe comorbidities or complications. 2.Intraoperative Exclusion Criteria: After obtaining informed consent, patients underwent appropriate radiofrequency ablation. Patients were further excluded from the study if any of the following occurred during the ablation procedure: (1) Attempted ablation via femoral artery access or inadvertent puncture of the femoral artery; (2) Occurrence of severe hemorrhage, thrombosis, or other serious complications during the procedure; (3) Difficulty with needle insertion or catheter sheath placement; (4) Incorrect positioning of the sheath. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-01 00:00:00至 To 2027-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-04-01 00:00:00 至 To 2027-07-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
采用计算机程序设定的区组随机化以1:1的比例随机分为试验组(手动压迫止血+绷带盐袋加压4小时后下地活动)和对照组(手动压迫止血+绷带盐袋加压6小时后下地活动) |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Block randomization set by computer program was randomly divided into test group (manual compression for hemostasis + bandage salt bag compression for 4 hours and then exercise on the ground) and control group (manual compression for hemostasis + bandage salt bag compression for 6 hours and then exercise on the ground) in a ratio of 1:1 |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
本次研究对以下人群实施盲法: (1)手术操作人员; (2)对主要研究结局进行评估的护士或者医师; (3)对结果进行统计分析人员。 |
|
Blinding: |
This study implemented blinding for the following groups of people: (1) Surgical operators; (2) Nurses or physicians evaluating the primary study outcomes; (3) Personnel conducting statistical analysis of the results. |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
None |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
电子采集管理系统 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Electronic capture management system |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |